Top Markets
#1 XPIN Network XPIN Network +21.86%
#2 Pons Pons +21.59%
#3 Geodnet Geodnet +20.76%
#4 The Black Bull The Black Bull +20.68%
#5 SSV Network SSV Network +19.58%
#6 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +19.58%
#7 Ore Ore +19.40%
#8 Derive Derive +18.88%
#9 Bitcoin Cash Bitcoin Cash +18.39%
#10 WhiteBIT Coin WhiteBIT Coin +18.09%
Coin of the day
XPIN Network XPIN Network
Settings
Language
ENGLISH
Currency
USD
Theme
Orexo AB Orexo AB

Orexo AB

ORX
Rank in Stocks #24964
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Share Price
$1.56
Market Cap
$54.77M
Change (1 day)
-0.43%
Change (1 year)
-29.25%
Country
SE
Trade Orexo AB (ORX)

Category

Healthcare
P/E ratio for Orexo AB (ORX)
P/E ratio as of 2026 TTM: 0
According to Orexo AB latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Orexo AB from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 24.32 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.13 -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 31.46 -
HK
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.